Effects of Carrelizumab Combined with Albumin-Bound Paclitaxel on Tumor Markers,Immune Function and Angiogenesis Indexes in Patients with Advanced Cervical Cancer
Objective:To observe the effect of carrelizumab combined with albumin-bound paclitaxel on immune function,tumor markers and angiogenesis indexes in patients with advanced cervical cancer.Methods:According to the random number table method,93 patients with advanced cervical cancer admitted to the Affiliated Huai'an Hospital of Xuzhou Medical University,Jiangsu Cancer Hospi-tal and Zhongda Hospital Affiliated to Southeast University from June 2019 to June 2023 were divided into control group(n=46,albu-min-bound paclitaxel treatment)and observation group(n=47,carrelizumab combine with albumin-bound paclitaxel treatment).The effi-cacy,tumor markers,immune function indexes,angiogenesis indexes and adverse reactions in two groups were compared.Results:The objective response rate(ORR)of the observation group was 44.68％,and the disease control rate(DCR)was 74.47％,which were higher than the control group's 21.74％and 50.00％,respectively(P＜0.05).After treatment,the levels of squamous cell carcinoma antigen(SCCA),carcinoembryonic antigen(CEA),carbohydrate antigen(CA)125,CA199,angiopoietin-2(Ang-2),vascular endothelial growth factor(VEGF)and CD8+in observation group were lower than those in control group,and the levels of CD3+,CD4+,CD4+/CD8+were higher than those in control group(P＜0.05).The total incidence of adverse reactions in control group was 34.78％,and that in observation group was 29.79％,there was no difference between two groups(P＞0.05).Conclusion:Carrelizumab combined with albumin-bound pa-clitaxel can reduce the level of tumor markers in patients with advanced cervical cancer,improve immune function,inhibit tumor angio-genesis,and effectively prevent disease progression.
NETL
NSTL
万方数据
